In its decision 24 April 2015, the Borgarting Court of Appeal upheld a decision from the Oslo District Court revoking Genentech’s Norwegian patent NO 323 557 (the ‘557-patent) which concerns formulations of pharmaceutical proteins, including trastuzumab. Trastuzumab is the active ingredient in Genentech’s product Herceptin.

Hospira successfully argued that the disputed claims of the ‘557-patent were invalid due to a lack of inventive step. The Court of Appealheld that the patent was nothing other than the result of a routine approach to the problem based on screening of commonly known additives, and the application of commonly known technology.

A full summary of this case has been published on Kluwer IP Law.


To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law